The highlighted topics concerning
Alnylam Pharmaceuticals are focused on the pharma giant's positive long-term results for AMVUTTRA as disclosed in the HELIOS-B study, which has sparked investor's interest. The firm's stocks exhibit promising growth trend with forecast ranging between $449-$583, while analysts continue to express optimism in Alnylam's profitability, maintaining a 'buy' rating.
BMO Capital echoes similar positive sentiment by increasing Alnylam's stock price target following Zilebesiran data. Despite a mid-stage setback,
Roche is eager to proceed to Phase 3 together with Alnylam for Zilebesiran development. Amid record revenue growth and strategic pipeline momentum, the Pharma firm has revised its 2025 revenue projection.
AMVUTTRA, a breakthrough drug for treating a rare disease, is expected to drive long-term value, while Alnylam got the green light from
EU for AMVUTTRA. Although Zilebesiran didn't significantly lower blood pressure in mid-stage study, Alnylam plans to initiate a CV events trial for the RNA interference drug.
Alnylam Pharmaceuticals News Analytics from Thu, 20 Mar 2025 07:00:00 GMT to Sat, 06 Sep 2025 14:21:50 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 5
